| News releases from Celgene International SÃ rl |  |
Apremilast Achieves Statistical Significance for the Primary and Major Secondary Endpoints in Fourth Pivotal Phase III Study (PALACE 4) of Patients with Psoriatic Arthritis
Source: Business Wire News Releases
May 06, 2013 02:27 PM
ABRAXANE® con gemcitabina demuestra una mejora estadísticamente significativa en el ensayo de supervivencia en pacientes con cáncer de páncreas avanzado en fase III
Source: Business Wire Spanish
January 23, 2013 12:10 AM
ABRAXANE® Plus Gemcitabine Demonstrates Significant Survival Advantage in Phase III Study of Patients with Advanced Pancreatic Cancer
Source: Business Wire News Releases
January 22, 2013 06:01 PM
Apremilast oral logra resultados estadísticamente significativos para el criterio de valoración principal ACR20 en el primer ensayo de Fase III (PALACE-1) en pacientes con artritis psoriásica
Source: Business Wire Spanish
November 14, 2012 06:53 AM
Oral Apremilast Achieves Statistical Significance for the Primary Endpoint of ACR20 in the First Phase III Study (PALACE-1) in Patients with Psoriatic Arthritis
Source: Business Wire News Releases
November 13, 2012 03:30 PM
ABRAXANE® muestra una mejoría estadísticamente significativa en la supervivencia general para los pacientes con cáncer pancreático avanzado en el ensayo de fase III
Source: Business Wire Spanish
November 10, 2012 07:28 PM
ABRAXANE® Demonstrates Statistically Significant Improvement in Overall Survival for Patients with Advanced Pancreatic Cancer in Phase III Study
Source: Business Wire News Releases
November 09, 2012 05:00 PM
ABRAXANE® demuestra una mejora significativa en la supervivencia libre de progresión en comparación con la quimioterapia estándar en pacientes con melanoma avanzado
Source: Business Wire Spanish
October 25, 2012 10:50 AM
ABRAXANE® Demonstrates Significant Improvement in Progression-Free Survival Compared to Standard Chemotherapy in Advanced Melanoma Patients
Source: Business Wire News Releases
October 25, 2012 07:20 AM
Observational Study Demonstrates No Greater Incidence of Progression to Acute Myeloid Leukemia with REVLIMID® in Patients with Lower-Risk Del(5q) Myelodysplastic Syndromes
Source: Business Wire News Releases
December 07, 2010 12:36 PM
Retrospective Analysis of Clinical Data from REVLIMID® Phase III Study (MDS-004) Reports a Significant Improvement in Survival and Risk Reduction in Disease Progression for Patients with del(5Q) Myelo
Source: Business Wire News Releases
December 07, 2010 07:30 AM
Clinical Data from Two Phase II Studies Evaluating REVLIMID® Plus Rituximab in Indolent Non-Hodgkin’s Lymphomas Presented at ASH
Source: Business Wire News Releases
December 07, 2010 01:26 AM
Data from Three Presentations Evaluating Clinical Benefit of Pomalidomide in Previously Treated Multiple Myeloma Presented at ASH
Source: Business Wire News Releases
December 06, 2010 09:40 PM
Updated Clinical Results from REVLIMID® Continuous Treatment Phase III Study Show Statistically Significant Improvement in Progression-Free Survival in Patients Newly Diagnosed with Multiple Myeloma
Source: Business Wire News Releases
December 06, 2010 05:16 PM
REVLIMID® Data in Patients with Multiple Myeloma Evaluating Surival Rates with Low- and High-Dose Dexamethasone with Respect to Age
Source: Business Wire News Releases
December 06, 2010 08:47 AM
New Clinical Data Evaluating ISTODAX® in Pivotal Open-Label Phase II Study for Patients with Peripheral T-Cell Lymphoma (PTCL)
Source: Business Wire News Releases
December 05, 2010 06:22 PM
Continuous Treatment with REVLIMID® for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant Evaluated by Intergroup Phase III Study (CALGB 100104)
Source: Business Wire News Releases
December 05, 2010 05:41 PM
Clinical Data Evaluating Oral REVLIMID® Either with Rituximab or Following Rituximab Combination for Patients with Chronic Lymphocytic Leukemia (CLL) Presented at ASH
Source: Business Wire News Releases
December 04, 2010 05:53 PM
Phase III Study Evaluating REVLIMID® in Patients with High-Risk Smoldering Multiple Myeloma Reported Statistically Significant Reduction in Risk of Disease Progression
Source: Business Wire News Releases
December 04, 2010 05:52 PM
More Than 100 Presentations and Posters Evaluating Celgene Products to Be Highlighted at Three Major Medical Meetings in June
Source: Business Wire News Releases
May 21, 2010 07:30 AM
Three Phase II Studies Evaluate the Combination of REVLIMID® and rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma
Source: Business Wire News Releases
December 08, 2009 12:48 PM
Multi-Centre, Randomised, Controlled Study Results Evaluating the Clinical Potential of REVLIMID® in Patients with Smoldering Multiple Myeloma Presented at ASH
Source: Business Wire News Releases
December 07, 2009 05:28 PM
First Interim Analysis after Less Than 10-Months of Phase III Study Shows That Continuous REVLIMID® Therapy is Superior to Fixed Duration Regimens in Newly Diagnosed Elderly Multiple Myeloma Patients
Source: Business Wire News Releases
December 07, 2009 03:45 PM
Two Studies Evaluating the Clinical Potential of Pomalidomide for the Treatment of Multiple Myeloma Patients Refractory to Novel Therapies Presented at the American Society of Hematology Meeting
Source: Business Wire News Releases
December 07, 2009 02:44 PM
First Randomised Study Comparing All-Oral REVLIMID® Regimen Compared to Autologous Stem Cell Transplant Presented at ASH
Source: Business Wire News Releases
December 07, 2009 01:41 PM
Landmark Study Published in The Lancet Oncology Shows Celgene’s Vidaza® Demonstrates Unprecedented Overall Survival in Intermediate-2 and High-Risk Myelodysplastic Syndromes, as Well as Acute Myeloid
Source: Business Wire News Releases
February 17, 2009 07:02 PM
European Commission Grants VIDAZA® Full Marketing Authorization for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (MDS) And Acute Myeloid Leukaemia (AML)
Source: Business Wire News Releases
December 23, 2008 12:09 PM
Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization from Health Canada for Treatment of Multiple Myeloma
Source: Business Wire News Releases
October 06, 2008 07:30 AM
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here